SG11202000881VA - Adjuvant therapy for use in prostate cancer treatment - Google Patents
Adjuvant therapy for use in prostate cancer treatmentInfo
- Publication number
- SG11202000881VA SG11202000881VA SG11202000881VA SG11202000881VA SG11202000881VA SG 11202000881V A SG11202000881V A SG 11202000881VA SG 11202000881V A SG11202000881V A SG 11202000881VA SG 11202000881V A SG11202000881V A SG 11202000881VA SG 11202000881V A SG11202000881V A SG 11202000881VA
- Authority
- SG
- Singapore
- Prior art keywords
- prostate cancer
- cancer treatment
- adjuvant therapy
- adjuvant
- therapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17184320 | 2017-08-01 | ||
PCT/EP2018/054470 WO2019025031A1 (en) | 2017-08-01 | 2018-02-23 | Adjuvant therapy for use in prostate cancer treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202000881VA true SG11202000881VA (en) | 2020-02-27 |
Family
ID=59520769
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202000881VA SG11202000881VA (en) | 2017-08-01 | 2018-02-23 | Adjuvant therapy for use in prostate cancer treatment |
Country Status (12)
Country | Link |
---|---|
US (2) | US11771705B2 (en) |
EP (1) | EP3661520B1 (en) |
JP (2) | JP2020530031A (en) |
CN (1) | CN111295192A (en) |
BR (1) | BR112020002094A2 (en) |
CA (1) | CA3071660A1 (en) |
ES (1) | ES2906380T3 (en) |
MY (1) | MY197942A (en) |
PL (1) | PL3661520T3 (en) |
RU (1) | RU2758386C2 (en) |
SG (1) | SG11202000881VA (en) |
WO (1) | WO2019025031A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU231240B1 (en) | 2019-09-03 | 2022-04-28 | Richter Gedeon Nyrt. | Industrial process for the preparation of high-purity estetrol |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5340585A (en) * | 1991-04-12 | 1994-08-23 | University Of Southern California | Method and formulations for use in treating benign gynecological disorders |
WO2004037269A1 (en) * | 2002-10-23 | 2004-05-06 | Pantarhei Bioscience B.V. | Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy |
ES2346053T3 (en) * | 2002-11-08 | 2010-10-08 | Pantarhei Bioscience B.V. | STERESIS OF STEROL THROUGH STEROIDS DERIVED FROM ESTRONA. |
CA2523830A1 (en) * | 2003-04-30 | 2004-11-11 | Debiopharm S.A. | Methods and compositions using gonadotropin hormone releasing hormone |
WO2005063276A1 (en) * | 2003-12-23 | 2005-07-14 | Debiopharm S.A. | Methods and compositions using gonadotropin hormone releasing hormone |
TW200950799A (en) * | 2008-05-07 | 2009-12-16 | Merrion Res Iii Ltd | Compositions of GnRH related compounds and processes of preparation |
JP2012077020A (en) * | 2010-09-30 | 2012-04-19 | Mochida Pharmaceut Co Ltd | Combination medicine of gestagen and gnrh antagonist |
-
2018
- 2018-02-23 EP EP18705663.5A patent/EP3661520B1/en active Active
- 2018-02-23 RU RU2020108631A patent/RU2758386C2/en active
- 2018-02-23 JP JP2020528505A patent/JP2020530031A/en active Pending
- 2018-02-23 PL PL18705663T patent/PL3661520T3/en unknown
- 2018-02-23 CN CN201880050362.8A patent/CN111295192A/en active Pending
- 2018-02-23 CA CA3071660A patent/CA3071660A1/en active Pending
- 2018-02-23 WO PCT/EP2018/054470 patent/WO2019025031A1/en unknown
- 2018-02-23 SG SG11202000881VA patent/SG11202000881VA/en unknown
- 2018-02-23 ES ES18705663T patent/ES2906380T3/en active Active
- 2018-02-23 MY MYPI2020000574A patent/MY197942A/en unknown
- 2018-02-23 BR BR112020002094-0A patent/BR112020002094A2/en unknown
-
2020
- 2020-01-30 US US16/777,600 patent/US11771705B2/en active Active
-
2023
- 2023-03-13 JP JP2023038362A patent/JP2023085303A/en active Pending
- 2023-08-24 US US18/237,837 patent/US20230405019A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
RU2020108631A (en) | 2021-09-02 |
EP3661520B1 (en) | 2021-12-01 |
WO2019025031A1 (en) | 2019-02-07 |
CA3071660A1 (en) | 2019-02-07 |
BR112020002094A2 (en) | 2020-07-28 |
MY197942A (en) | 2023-07-25 |
JP2020530031A (en) | 2020-10-15 |
US11771705B2 (en) | 2023-10-03 |
JP2023085303A (en) | 2023-06-20 |
CN111295192A (en) | 2020-06-16 |
ES2906380T3 (en) | 2022-04-18 |
PL3661520T3 (en) | 2022-03-28 |
US20230405019A1 (en) | 2023-12-21 |
RU2020108631A3 (en) | 2021-09-02 |
US20200246354A1 (en) | 2020-08-06 |
EP3661520A1 (en) | 2020-06-10 |
RU2758386C2 (en) | 2021-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL290149A (en) | Combination therapy for cancer treatment | |
HK1247129A1 (en) | Combination therapy for the treatment of cancer | |
IL267795A (en) | Combination therapy for the treatment of cancer | |
IL255060A0 (en) | Combination therapy for treating cancer | |
HK1251475A1 (en) | Combination therapy for the treatment of cancer | |
IL282663A (en) | Bt1718 for use in treating cancer | |
PT3609497T (en) | Combination therapy for prostate cancer | |
PL3253208T3 (en) | Combination therapies for use in the treatment of breast cancer | |
IL275517A (en) | Methods and combination therapy to treat cancer | |
IL280830A (en) | Conjugates for use in methods of treating cancer | |
IL266993A (en) | Combination therapy for the treatment of cancer | |
PL3258931T3 (en) | Use of cabazitaxel in the treatment of prostate cancer | |
IL281281A (en) | Combination therapy for the treatment of prostate cancer | |
IL269121A (en) | Usl-311 for use in the treatment of cancer | |
SG11202000881VA (en) | Adjuvant therapy for use in prostate cancer treatment | |
GB201704909D0 (en) | Cancer therapy | |
ZA202001435B (en) | Abx196 for use in the treatment of bladder cancer | |
IL253642A0 (en) | Combination therapy for the treatment of cancer | |
GB201711855D0 (en) | Cancer therapy | |
GB2578008B (en) | 1-Acetyl-5-Nitro-4-Phenyl-3-Pyrrolin-2-one for use in cancer treatment | |
GB201612794D0 (en) | Therapeutic use of diethanololeamide in prostate cancer treatment | |
EP3706752A4 (en) | Combination therapy for cancer treatment | |
GB201711250D0 (en) | Cancer therapy | |
GB201710198D0 (en) | Cancer therapy | |
GB201704474D0 (en) | Combination therapy for treatment of cancer |